Uveitis as a result of MAP kinase pathway inhibition

Case Reports in Ophthalmology

Volumn 4, Issue 3, 2013, Pages 279-282

  Joshi, Lavnish ^a   Karydis, Andreas ^a   Gemenetzi, Maria ^a   Shao, Emily H ^a   Taylor, Simon R J ^a,b  

^a ROYAL SURREY COUNTY HOSPITAL   (United Kingdom)

^b IMPERIAL COLLEGE LONDON   (United Kingdom)

Author keywords

Dabrafenib; Melanoma; Trametinib; Uveitis

Indexed keywords

DABRAFENIB; IBUPROFEN; MITOGEN ACTIVATED PROTEIN KINASE INHIBITOR; TRAMETINIB; MITOGEN ACTIVATED PROTEIN KINASE;

ADULT; ANAMNESIS; ARTICLE; BRAF GENE; CANCER LOCALIZATION; CANCER STAGING; CASE REPORT; CENTRAL SEROUS RETINOPATHY; CUTANEOUS MELANOMA; DIFFERENTIAL DIAGNOSIS; DRUG INDUCED DISEASE; DRUG WITHDRAWAL; ENDOPHTHALMITIS; FEVER; FLUORESCENCE ANGIOGRAPHY; GENE; HUMAN; MALAISE; MALE; MIDDLE AGED; PRIORITY JOURNAL; REPEATED DRUG DOSE; RETINA DEGENERATION; RETINA VEIN OCCLUSION; SENTINEL LYMPH NODE BIOPSY; UVEITIS; VITREOUS FLOATERS; VITRITIS; CLINICAL TRIAL; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; ENZYME INHIBITION; HUMAN TISSUE; LATE OPTIC DISC LEAKAGE; ONCOGENE; OPTIC DISK ANOMALY; TUMOR VOLUME; VISUAL ACUITY;

EID: 84893089529     PISSN: None     EISSN: 16632699     Source Type: Journal    
DOI: 10.1159/000357060     Document Type: Article

References (8)

1. Adamina M, Joerger M: Dose-toxicity models in oncology. Expert Opin Drug Metab Toxicol 2011;7:201-211.
2. Renouf DJ, Velazquez-Martin JP, Simpson R, Siu LL, Bedard PL: Ocular toxicity of targeted therapies. J Clin Oncol 2012;30:3277-3286.
3. Leijen S, Middleton MR, Tresca P, Kraeber-Bodere F, Dieras V, Scheulen ME, Gupta A, Lopez-Valverde V, Xu ZX, Rueger R, et al: Phase I dose-escalation study of the safety, pharmacokinetics, and pharmacodynamics of the MEK inhibitor RO4987655 (CH4987655) in patients with advanced solid tumors. Clin Cancer Res 2012;18:4794-4805.
4. Menzies AM, Long GV, Murali R: Dabrafenib and its potential for the treatment of metastatic melanoma. Drug Des Devel Ther 2012;6:391-405.
5. van der Noll R, Leijen S, Neuteboom GH, Beijnen JH, Schellens JH: Effect of inhibition of the FGFR-MAPK signaling pathway on the development of ocular toxicities. Cancer Treat Rev 2013;39:664-672.
6. Huang W, Yang AH, Matsumoto D, Collette W, Marroquin L, Ko M, Aguirre S, Younis HS: PD0325901, a mitogen-activated protein kinase kinase inhibitor, produces ocular toxicity in a rabbit animal model of retinal vein occlusion. J Ocul Pharmacol Ther 2009;25:519-530.
7. de Smet MD, Taylor SR, Bodaghi B, Miserocchi E, Murray PI, Pleyer U, Zierhut M, Barisani-Asenbauer T, LeHoang P, Lightman S: Understanding uveitis: the impact of research on visual outcomes. Prog Retin Eye Res 2011;30:452-470.
8. Tempest-Roe S, Joshi L, Dick AD, Taylor SR: Local therapies for inflammatory eye disease in translation: past, present and future. BMC Ophthalmol 2013;13:39.